Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Censoring Survival Data01:09

Censoring Survival Data

80
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
80
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

122
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
122
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

129
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
129
Test for Homogeneity01:23

Test for Homogeneity

2.0K
The goodness–of–fit test can be used to decide whether a population fits a given distribution, but it will not suffice to decide whether two populations follow the same unknown distribution. A different test, called the test for homogeneity, can be used to conclude whether two populations have the same distribution. To calculate the test statistic for a test for homogeneity, follow the same procedure as with the test of independence. The hypotheses for the test for homogeneity can...
2.0K
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

194
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
194

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistics and AI - A Fireside Conversation.

Harvard data science review·2026
Same author

Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for Implementation.

Statistics in medicine·2026
Same author

Predicting the timing of first sustained cognitive worsening in Alzheimer's disease using real-world clinical data and machine learning.

medRxiv : the preprint server for health sciences·2026
Same author

Nonparametric estimation of the total treatment effect with multiple outcomes in the presence of terminal events.

Biometrics·2026
Same author

Using principal progression rate to quantify and compare disease progression in comparative studies.

Journal of biopharmaceutical statistics·2026
Same author

Stratification of Alzheimer's disease patients using knowledge-guided unsupervised latent factor clustering with electronic health record data.

Communications medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

Assessing heterogeneity in surrogacy using censored data.

Layla Parast1, Lu Tian2, Tianxi Cai3

  • 1Department of Statistics and Data Sciences, The University of Texas at Austin, Austin, Texas.

Statistics in Medicine
|May 30, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces a new statistical method to assess if a surrogate marker

Keywords:
biomarkernonparametricsurvivaltreatment effect

More Related Videos

Mouse Round Spermatid Injection
08:41

Mouse Round Spermatid Injection

Published on: January 26, 2024

714
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.6K

Related Experiment Videos

Last Updated: Jun 25, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
Mouse Round Spermatid Injection
08:41

Mouse Round Spermatid Injection

Published on: January 26, 2024

714
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.6K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Epidemiology

Background:

  • Evaluating surrogate markers in clinical studies is complex.
  • Existing statistical methods often fail to account for heterogeneity in surrogate marker utility.
  • Censored data, common in long-term studies, presents a challenge for current surrogate evaluation methods.

Purpose of the Study:

  • To develop a robust nonparametric approach for assessing heterogeneity in surrogate marker utility.
  • To create a testing procedure for evaluating this heterogeneity in censored time-to-event data.
  • To investigate the relationship between glycemic control, diabetes, and sex hormones using this new method.

Main Methods:

  • Developed a novel nonparametric statistical approach for assessing heterogeneity in surrogate marker utility.
  • Proposed and evaluated a testing procedure for heterogeneity in censored time-to-event outcomes.
  • Utilized simulation studies to examine the finite sample performance of the proposed methods.

Main Results:

  • The developed nonparametric approach effectively assesses heterogeneity in surrogate marker utility.
  • The proposed testing procedure can formally test for heterogeneity at single or multiple time points.
  • Simulations demonstrated the reliability of the estimation and testing procedures.

Conclusions:

  • The new method provides a robust way to assess heterogeneity in surrogate marker utility with censored data.
  • This approach is valuable for understanding how surrogate marker performance varies across patient characteristics.
  • The method was successfully applied to analyze surrogate marker relationships in the Diabetes Prevention Program study.